Most of these studies examined all-trans retinoic acid (RA)
A small percentage of patients receive either valproic acid or sodium valproate as solid dosage forms or sodium valproate as solid and liquid dosage forms
Disclosures: Antonio Moreno: Nothing to Disclose, Thomas Issa: Nothing to Disclose, Douglas Farmer: Nothing to Disclose, Edward Wolfgang Lee: Nothing to Disclose 2224 STATIN USE IN CIRRHOSIS CAN DECREASE RISK OF PORTAL HYPERTENSION AND MORTALITY Muhammad Ali Butt 1 Taimur Muzammil 1 Rahul Karna 2 Himsikhar Khataniar 1 Nabeeha Mohy-ud-din 3 , 1 Allegheny General Hospital, Pittsburgh, PA, 2 University of Minnesota Medical Center, 3 Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA Background: MASLD related cirrhosis is one of the leading etiologies of liver disease, and these patients frequently have other comorbidities like atherosclerotic cardiovascular disease (ASCVD), hyperlipidemia (HLD), cerebrovascular disease (CVD), and diabetes mellitus (DM)
Patients were instructed to report any nausea incidence or intestinal disturbance, no matter how slight
To view a copy of this licence, visit About this article Cite this article Narsinh, K.H., Perez, E., Haddad, A.F
Finally, we will conduct a data-driven comparison of GHK-Cu peptide therapy against conventional treatments for hair loss and skin aging, empowering you with the knowledge to make informed decisions
